Kestra Reports Q3 Revenue of $24.55M, Exceeding Expectations
Reports Q3 revenue $24.55M, consensus $22.87M. "Kestra delivered another strong quarter of financial performance, generating revenue growth of 63% while expanding gross margin to over 52%," said Brian Webster, president and CEO. "We also continued to execute on several key operational objectives, including rapid growth of the commercial organization, release of compelling primary results from our FDA post-approval study, fortification of our balance sheet with an equity offering, and entrance into a strategic collaboration with Biobeat Technologies. As we progress on our journey to category leadership, our team remains focused on growing the wearable defibrillator market and executing on our commitments to patients and their prescribers."
